MedTrace Logo

Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness

NCT05603143 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 468

Last updated 2024-12-20

Study results available
· View outcomes & findings →

Summary

The goal of this clinical study is to test how well the study drug, obeldesivir (GS-5245), works and how safe it is in treating coronavirus disease 2019 (COVID-19) in participants that have a higher risk of getting a serious illness.

Conditions

Interventions

DRUG

Obeldesivir

Tablets administered orally without regard to food.

DRUG

Obeldesivir Placebo

Placebo tablets administered orally without regard to food.

Sponsors & Collaborators

Principal Investigators

  • Gilead Study Director · Gilead Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-05
Primary Completion
2023-11-07
Completion
2023-11-07
FDA Drug
Yes

Countries

  • Brazil
  • Bulgaria
  • Canada
  • France
  • Hungary
  • Italy
  • Japan
  • Mexico
  • Poland
  • Portugal
  • Romania
  • Singapore
  • South Africa
  • South Korea
  • Spain
  • Taiwan
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05603143 on ClinicalTrials.gov